Ann: MSB Partner JCR Files for Product Approval, page-44

madamswer:

Frankly, I'm not interested in proving subterfuge. You aren't behaving consistently at all.

Indeed, you never expressly said you didn't make the claim about doing the research on biotechs using shorting data as a key to valuation..
Seriously? I've followed up many times on this point, asking for further information and it took you until now to make any comment on it.

Now it's simply that I am supposed to find it within your parameters. But the content will not appear on a search. Search results are limited, see?

BTW I made general comment on intellectual rigour and I stand by it.

To say it's highly personalised is stretching things.

Enough diversions.

Madamswer can't seem to understand that TEVA is an expert on valuing biotechs. They put millions into doing a takeover.

Millions of US dollars.

You're putting your admitted ignorance on how to value bios against that, and saying what?

We should ignore it?

That's not highly personalised either by the way, it's basic logic.